Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Adjuvanted VZV subunit vaccine gE/AS01B is more immunogenic than Varilrix

Nov. 4, 2010

Panobinostat has antitumor activity in phase II trial in SCLC

Nov. 4, 2010

AMG-386 is active in renal cell carcinoma and ovarian cancer

Nov. 4, 2010

ENB-0040 shows promise to treat hypophosphatasia in children

Nov. 4, 2010

Clinical data reported on cilengitide in NSCLC and glioblastoma

Nov. 3, 2010

Afatinib is active in patients with head and neck and lung cancers

Nov. 3, 2010

Manageable toxicity seen with brivanib alaninate plus cetuximab and irinotecan in colorectal cancer

Nov. 3, 2010

Antibodies targeting LINGO-1 promote myelination in preclinical studies

Nov. 3, 2010

Azathioprine and prednisolone reduce relapse rates in neuromyelitis optica

Nov. 3, 2010

Mild toxicity and disease stabilizations seen with L19TNF-alpha in patients with cancer

Nov. 2, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...